All In MedTech

Device Trial Radar · NCT04210427

Cystic Fibrosis and Gut Dysmotility: The Effect of Polyethylene Glycol (PEG) on Intestinal Transit

Last checked: Nov 19, 2026Latest source record: Aug 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

3

Actual

Start

Dec 12, 2019

Primary completion

Jun 6, 2023

Study completion Jun 6, 2023

Sponsor

Lead sponsor
St. Louis UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 24, 2019

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The investigators will recruit 15 patients with cystic fibrosis 18 years of age and older who present with constipation. The investigators will assess baseline motility symptoms with a survey. Patients will then ingest a SmartPill (trademark) to obtain baseline motility within the GI lumen. All patients will undergo intervention with taking polyethylene glycol (PEG) or Miralax (brand name) 17 grams once daily. After two weeks of therapy, the patient will repeat the motility survey and again ingest a smart pill to assess the change in motility symptoms while on therapy.

Conditions

  • Cystic Fibrosis Gastrointestinal Disease

Interventions

  • Polyethylene Glycol 3350Drug

    All patients will undergo intervention with taking polyethylene glycol (PEG) or Miralax (brand name) 17 grams once daily for total of 2 weeks.

  • SmartPill Motility System & PillCam Patency CapsuleDevice

    Patients will ingest a Smart pill to obtain baseline motility within the GI lumen. After two weeks of therapy, the patient will repeat the motility survey and again ingest a smart pill to assess the change in motility symptoms while on therapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change is Being Assessed: Total Intestinal Transit Time at Baseline and Two Weeks Following Initiation of TherapyTime frame: Change is being assessed: total intestinal transit time (measured in hours) at baseline and two weeks following initiation of therapy with PEG
  2. Number of Participants With IBS at Baseline and 2 Weeks Post BaselineTime frame: Baseline and 2 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • SSM Health Cardinal Glennon Children's Hosptial

    St Louis, Missouri

  • SSM Health Saint Louis University Hosptial

    St Louis, Missouri

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.